Cardiome Pharma (CRME) Misses Q3 EPS by 10c

Cardiome Pharma (NASDAQ: CRME) reported Q3 EPS of ($0.31), $0.10 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $5 million versus the consensus estimate of $7.08 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• DA Davidson Reiterates Buy Rating on Boost Run (BRUN)
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22